Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137784 · ClinicalTrials.gov registry record · Phase 2
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT03137784 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 148 participants.
The verdict
NCT03137784, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
Interventions
- DRUG Placebo
- DRUG NVA237 (glycopyrronium bromide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2017-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137784
The ClinicalTrials.gov registry entry for NCT03137784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03137784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137784 about?
NCT03137784 is a clinical study titled "Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma". The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
What is the current status of trial NCT03137784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2017-05-04. Estimated completion is 2017-12-29.
What interventions are being tested in trial NCT03137784?
The interventions under investigation include: Placebo (DRUG), NVA237 (glycopyrronium bromide) (DRUG).
Who is sponsoring clinical trial NCT03137784?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.